Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with inv(16)(p13q22) as a sole genetic abnormality.

Abstract

Inversion of chromosome 16, inv(16)(p13q22), juxtaposes the core binding factor beta (CBFB) and myosin heavy chain 11 (MYH11) genes, resulting in a myeloid leukemic disease phenotype characterized by increased bone marrow and peripheral blood blasts with myelomonocytic antigen expression and an accompanying eosinophilia. This cytogenetic abnormality has been reported in a variety of other neoplasms, in which it generally occurs as part of a complex karyotype, including rare B-lineage non-Hodgkin lymphomas. We report a case of clinically, morphologically, and immunologically typical lymphoplasmacytic lymphoma/Waldenström macroglobulinemia in which a majority of the malignant cells had an inv(16)(p13q22) as a sole abnormality. We review the literature and discuss the possible role of this genetic lesion in B-cell neoplasia.

• Authors: John L Frater, Mona Mirkhaef, Jacqueline R Batanian
• Journal: Cancer genetics and cytogenetics (Cancer Genet Cytogenet) Vol. 174 Issue 2 Pg. 161-5 (Apr 15 2007) ISSN: 0165-4608 [Print] United States
• PMID: 17452259 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• Rituximab

Topics

• Aged, 80 and over
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents (therapeutic use)
• Chromosome Banding
• Chromosome Inversion
• Chromosomes, Human, Pair 16
• Fatal Outcome
• Humans
• In Situ Hybridization, Fluorescence
• Karyotyping
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, genetics, pathology)
• Male
• Rituximab
• Waldenstrom Macroglobulinemia (drug therapy, genetics, pathology)